Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

Summary

This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.

Timeline

Start

2021-05-03

Primary completion

2023-05-18

Completion

2024-06-10

Outcome

Met primary endpoint

release “The study met the primary objective of demonstrating safety and tolerability in all 12 participants in the study’s low and high dose cohorts” bayer.com ↗

Drugs

Indications